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Identical decline of residual renal function in high-flux biocom- renal function has been lost [1]. The capacity to increase
patible hemodialysis and CAPD. small solute clearance using larger dialyzers, increased
Background. Patients on conventional hemodialysis lose re- blood and dialysis fluid flow rates, and increased treat-sidual renal function more rapidly than patients on continuous
ment times has meant that the maintenance of adequateambulatory peritoneal dialysis (CAPD). The effect of dialysis
hemodialysis (HD) is much less dependent on residualusing synthetic membranes and ultrapure water is less clear.
Methods. The decline of urea clearance was compared in a renal function. Because of this, and the notion that resid-
cohort of 475 incident end-stage renal failure patients who ual renal function is lost more rapidly in HD than in
received treatment with CAPD (N  175) or hemodialysis CAPD [2–5], the practice has evolved in many units to(HD) utilizing high-flux polysulphone membranes, ultrapure
prescribe HD without reference to residual renal func-water, and bicarbonate as the buffer (N  300).
tion. Current interest in the concept of incremental dial-Results. CAPD patients were significantly younger, fitter
(lower comorbidity severity score), less dependent (higher Kar- ysis [6] challenges this practice and highlights the impor-
nofsky performance score) and less likely to have presented tance of residual renal function in HD as well as CAPD.
late than HD patients. There was no difference in the mean Preservation of residual renal function is emerging as anurea clearance in each group at dialysis initiation, or at any
important therapeutic goal [7]. There have been sugges-6-month time point during the ensuing 48 months. This was
tions that use of modern synthetic membranes may re-true even after exclusion of patients who had died in the first
year after initiation, those transferred to another dialysis mod- duce the rate of loss of residual renal function in HD,
ality, or those who had been transplanted. Only age and chronic though this is still controversial [8–11]. If this were true
interstitial disease predicted retention of urea clearance at one
then preservation of residual renal function may be ayear. The rate of decline of urea clearance was similar in pre-
further indication for use of such membranes. To investi-and post-dialysis initiation phases, though there may have been
a step-decline of about 2 mL/min at initiation, which requires gate this hypothesis, we studied the rate of decline of
further investigation. residual renal function before and after dialysis initiation
Conclusions. In hemodialysis using high-flux biocompatible in a large group of incident end-stage renal failure (ESRF)
membranes and ultrapure water, residual renal function declines
patients treated in a single center. Our aim was to analyzeat a rate indistinguishable from that in CAPD. This may have
the impact of dialysis initiation and dialysis modality onimportant implications, since preservation of residual renal func-
tion has major benefits and is a valid therapeutic goal. the rate of decline of residual renal function.
METHODSDuring the past decade it has been recognized that
Patientsresidual renal function makes a crucial contribution to
the adequacy of continuous ambulatory peritoneal dial- We studied all patients beginning dialysis in the Lister
ysis (CAPD), such that the technique is often not viable Renal unit between January 1, 1990 and June 30, 1997.
in patients of above average body size, once residual Patients transferred from other units who were already
on dialysis were excluded. Patients who started dialysis
in our unit but were subsequently transferred out alsoKey words: ultrapure water, dialysis, incremental dialysis, peritoneal
were excluded. There were no other exclusions.dialysis, urea kinetic modelling, residual renal function, high-flux mem-
branes.
Hemodialysis program
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branes (5.1%) were used in a small minority of patients. KRU (mL/min)  2(UID · VID)/tID(Cpost  Cpre)
Dialyzers were reused using peracetic acid (Renalin;
where UID was defined as the urinary urea concentrationMinntec Inc., Minneapolis, MN, USA) as the main pro-
(mmol/L) in interdialytic urine collection; VID, volumecessing agent. Minimum reuse was zero (in hepatitis-
of interdialytic urine collection (mL); tID, duration ofpositive patients) and the maximum was 21 with a mean
interdialytic urine collection (min); Cpost, post-dialysisof 8. Bicarbonate was used exclusively as the buffer.
urea concentration (mmol/L); and Cpre, pre-dialysis ureaUltrapure water was used for dialysis and for the reuse
concentration (mmol/L).procedure. Water quality was regularly monitored to
In pre-dialysis and CAPD patients, residual renalensure tight bacteriological standards. The standards for
function was calculated from a 24-hour urine collectiondialysis fluid were zero cfu/mL and 0.015 EU/mL.
and the plasma urea concentration at the end of theSymptomatic hypotension occurred in 9.6% of all HD
collection.sessions. From 1993 an increasing proportion of patients
were treated by on-line hemodiafiltration, with selection KRU (mL/min)  (U · V)/(1440 · P)
favoring patients with poor residual renal function
where U is the urinary urea concentration in 24-hour(KRU1 mL/min), and those with large body size. Dial-
urine collection (mmol/L), V is the volume of the 24-hourysis was prescribed and monitored using a two-pool ki-
urine collection (mL), P is the plasma urea concentrationnetic model to ensure a dialysis dose (Kt/V) of 1.0 to
at end of the 24-hour urine collection (mmol/L).1.2 (per dialysis) for thrice weekly dialysis. Twice weekly
dialysis was used in a small proportion of patients Data gathering
(10%) usually for a few months after initiation. The
The following information was collected for all patients:Kt/V target for twice weekly dialysis was 2.0 per dialysis.
age, sex, nature of underlying renal disease, presence orAll Kt/V targets were a composite of Kt/Vrenal and Kt/
absence of diabetes, comorbidity score [12], KarnofskyVdialysis. To achieve this target the residual renal function
performance score (KPS) [13], date of dialysis initiation,was monitored at least three-monthly (see below).
planned or unplanned initiation [12], dialysis modality
at initiation, all estimates of KRU with correspondingCAPD program
date, all changes of dialysis modality and correspondingAll patients were treated using disconnect systems.
date; the duration of drug therapy including angiotensin-From 1 January 1992 the CAPD prescription was individ-
converting enzyme inhibitors (ACE-I), Angiotensin re-ualized to attempt to deliver a daily total Kt/V (residual
ceptor antagonists (A2A), aminoglycosides, non-steroi-renal plus dialysis) of at least 0.25. To achieve this, ex-
dal anti-inflammatory drugs (NSAIDs) and diuretics,change volumes were increased as residual renal function
and finally, the numbers of coronary, peripheral anddeclined. Residual renal function was measured at least
renal arteriograms performed after dialysis initiation.three-monthly. A small proportion of patients (10%)
were transferred to automated peritoneal dialysis (APD)
Definition of groupsmodes with the intention of maintaining adequacy when
Three study groups were defined.residual renal function had reached minimal levels (usu-
Group 1. First planned dialysis modality. The first modeally when KRU 1 mL/min).
of treatment in patients who presented for dialysis in a
Predialysis program planned fashion, and the modality at three months after
initiation in those presenting late (unplanned).From 1992 urea clearance was regularly measured in
Group 2. Sole dialysis modality. This group comprisedpatients approaching ESRD.
patients who did not change modality throughout follow-
Modality selection up period.
Group 3. Pre-dialysis follow-up group. All patientsPatients were allowed free choice of modality subject
with at least one estimate of KRU in both the last sixto a number of clinical imperatives. Previous extensive
months before dialysis initiation and during the first sixabdominal surgery, multiple abdominal herniae, signifi-
months after dialysis initiation were placed in this group.cant respiratory problems, and social dependency miti-
gated against the choice of CAPD. Age and underlying
Analysisrenal disease were not selection criteria.
All KRU measurements, even zero values, were in-
Measurements of residual renal function cluded in the analysis.
Comparison of rate of decline of residual renal func-In hemodialysis patients, the urea clearance (KRU)
tion. In the first planned modality and the sole modalitywas calculated from an interdialytic urine collection and
groups, KRU was plotted against time since the initiationthe mean interdialytic urea concentration (the mean of
the pre- and post-dialytic plasma urea concentrations). of dialysis for both hemodialysis and CAPD patients.
McKane et al: Biocompatible HD258
Table 1. Patient characteristics in the two groups according to first Caribbean. Sixty-five percent were male. Twenty-two per-
planned mode of dialysis cent were diabetic.
HD CAPD Significance (P)
Study groupsAge years 62.214.8 56.616.2 0.001
Male:female 2.06:1 1.57:1 NS Three hundred patients received hemodialysis (HD)
Diabetics 20.7% 25.7% NS and 175 received CAPD as their first planned dialysisUnplanned (acute)
modality. Of the CAPD patients in this group, 129 pa-presentation 47.3% 20% 0.001
Comorbidity severity tients received CAPD as their first modality and 46 late-
score 2.32.2 1.51.8 0.001 presenting patients converted to CAPD a mean of 1.3
KPS at dialysis
months after initiation of dialysis. Two hundred andinitiation 58.525.4 73.619.7 0.001
Mean BP at dialysis ninety-one patients received HD and 85 patients re-
initiation mm Hg 10719.7 10517.9 NS ceived CAPD as their sole dialysis modality. The pre-
Mean BP (average) 10510.9 1049.3 NS
dialysis follow-up group consisted of 206 patients.Nephrotics 25.4% 19.3% NS
Abbreviations are: HD, hemodialysis; CAPD, continuous ambulatory perito- Determinants of choice of modalityneal dialysis; KPS, Karnofsky performance score; BP, blood pressure.
First planned dialysis modality. Patients receiving
CAPD as their first planned modality were significantly
younger, fitter, less dependent and more likely to haveThe mean KRU in each group at each time point was
a planned initiation of dialysis than patients receivingcompared using an unpaired t test. To exclude potential
HD as the first planned modality (Table 1). More CAPDproblems with informative censoring, comparisons be-
than HD patients were female and more were diabetic,tween the hemodialysis and CAPD groups were performed
but these differences were not significant. The modalitybefore and after exclusion of the following groups of
groups did not differ with respect to ethnic composition.patients: (i) patients whose initiation onto dialysis had
Their diagnoses were similar except for a slight prepon-been unplanned; (ii) those dying during the first year after
derance of diabetes and polycystic kidney disease in theinitiation; (iii) patients transplanted at any time during
CAPD group, which are conditions more likely to befollow-up; (iv) if they were above the age of 70, (v) dia-
associated with planned initiation of dialysis. Using thebetics, and (vi) those who had any peritonitis episode.
significant factors in logistic regression analysis, the esti-Determinants of loss of KRU. Logistic regression anal-
mated odds of choice for CAPD were decreased to 0.83ysis was performed to determine which factors predicted
for each decade increase in age and to 0.41 by unplannedthe residual function retained (KRU1 mL/min) at one,
initiation of dialysis. The odds increased to 1.12 for eachtwo, and three years.
step rise in KPS and to 1.48 in females. ComorbidityInfluence of dialysis initiation on rate of loss of KRU. In
severity score was not an independent predictor of firstthe pre-dialysis follow-up group, KRU was plotted against
planned modality choice in this model (Table 2).time before dialysis initiation in the predialysis patients,
Sole dialysis modality. There were similar differencesand against time after dialysis initiation in the same pa-
between CAPD and HD patients in the sole dialysistients post-dialysis. To counter the potential bias of more
modality. CAPD patients were younger than HD pa-frequent sampling in the early months of hemodialysis,
tients (53.8  16.2 vs. 62.3  14.7 years, P  0.001),the mean KRU values were calculated for each patient
more fit (comorbidity severity score 1.12 1.64 vs. 2.29in each six-month period. Differences in mean KRU
2.21, P  0.001), and less dependent (KPS at dialysisbetween hemodialysis and CAPD patients (first planned
initiation 80.7  13.8 vs. 58.2  25.5, P  0.001). Un-modality criteria) at each six-month time point were
planned dialysis initiation was more common in HD pa-tested by the unpaired t test. To exclude patients with
tients (47.4% vs. 7%, P  0.001). More CAPD thanrapidly declining renal function, cases were selected from
HD patients were female (45.9% vs. 31.3%: P  0.014).the pre-dialysis follow-up group who had at least one
Female sex was a strong independent predictor of CAPDKRU value at least 18 months prior to dialysis initiation.
as the sole dialysis modality, along with younger age andSeparate exponential curves were fitted through mean
higher KPS. The odds of CAPD being the sole modalityKRU values at times before and after dialysis initiation.
were reduced by higher comorbidity and were dramati-The analytical packages used were Microsoft Excel
cally reduced (estimated odd ratio 0.12) in patientsand SPSS version 10.
whose initiation of dialysis was unplanned (Table 3).
RESULTS Rate of loss of urea clearance according to
dialysis modalityPatients
Four hundred and seventy-five patients were included First planned modality group. The rate of loss of KRU
was identical in HD and CAPD patients. There were noin the study. Their mean age was 60.2 15.6 (SD). Ninety
percent of patients were white, 7% Asian, and 3% Afro significant differences in the mean KRU values in HD
McKane et al: Biocompatible HD 259
Table 2. Predictors of continuous ambulatory peritoneal dialysis (CAPD) as first planned modality by logistic regression analysis
95.0% CI for odds ra-
tio
Wald Significance Estimated
B SE statistic (P) odds ratio Lower Upper
Step 1
Unplanned dialysis initiation 0.889 0.247 12.918 0.000 0.411 0.253 0.668
Age 10 years 0.149 0.054 7.554 0.006 0.861 0.774 0.958
KPS 10 points 0.102 0.035 8.605 0.003 1.107 1.034 1.185
Comorbidity each point 0.101 0.058 3.083 0.079 0.904 0.807 1.012
Female gender 0.336 0.214 2.469 0.116 1.399 0.920 2.126
Diabetes 0.273 0.247 1.229 0.268 1.314 0.811 2.131
Non-European 0.099 0.331 0.090 0.764 0.906 0.473 1.733
Step 2
Unplanned dialysis initiation 0.900 0.244 13.546 0.000 0.407 0.252 0.657
Age 10 years 0.148 0.054 7.472 0.006 0.863 0.776 0.959
KPS 10 points 0.099 0.034 8.681 0.003 1.104 1.034 1.180
Comorbidity each point 0.100 0.057 3.014 0.083 0.905 0.809 1.013
Female gender 0.334 0.213 2.447 0.118 1.396 0.919 2.122
Diabetes 0.262 0.243 1.158 0.282 1.299 0.806 2.094
Step 3
Unplanned dialysis initiation 0.933 0.243 14.770 0.000 0.393 0.244 0.633
Age 10 years 0.139 0.053 6.834 0.009 0.870 0.784 0.966
KPS 10 points 0.099 0.034 8.615 0.003 1.104 1.033 1.179
Comorbidity each point 0.091 0.056 2.589 0.108 0.913 0.818 1.020
Female gender 0.354 0.212 2.785 0.095 1.425 0.940 2.161
Step 4
Unplanned dialysis initiation 0.892 0.240 13.786 0.000 0.410 0.256 0.656
Age 10 years 0.189 0.044 18.538 0.000 0.828 0.759 0.902
KPS 10 points 0.114 0.032 12.423 0.000 1.121 1.052 1.194
Female gender 0.397 0.211 3.560 0.059 1.488 0.985 2.248
Table 3. Predictors of continuous ambulatory peritoneal dialysis (CAPD) as sole modality by logistic regression analysis
95.0% CI for odds ratio
Wald Significance Estimated
B SE statistic (P) odds ratio Lower Upper
Step 1
Unplanned dialysis initiation 2.081 0.468 19.766 0.000 0.125 0.050 0.312
Age 10 years 0.236 0.078 9.105 0.003 0.790 0.678 0.921
KPS 10 points 0.111 0.048 5.329 0.021 1.118 1.017 1.228
Comorbidity each point 0.205 0.088 5.434 0.020 0.815 0.686 0.968
Female gender 0.667 0.290 5.280 0.022 1.949 1.103 3.443
Diabetes 0.041 0.347 0.014 0.907 0.960 0.486 1.897
Non-European 0.419 0.468 0.801 0.371 0.658 0.263 1.646
Step 2
Unplanned dialysis initiation 2.075 0.465 19.876 0.000 0.126 0.050 0.313
Age 10 years 0.237 0.077 9.353 0.002 0.789 0.678 0.918
KPS 10 points 0.111 0.048 5.365 0.021 1.118 1.017 1.228
Comorbidity each point 0.206 0.087 5.635 0.018 0.814 0.686 0.965
Female gender 0.663 0.287 5.311 0.021 1.940 1.104 3.407
Non-European 0.421 0.467 0.811 0.368 0.657 0.263 1.641
Step 3
Unplanned dialysis initiation 2.127 0.462 21.177 0.000 0.119 0.048 0.295
Age 10 years 0.229 0.077 8.921 0.003 0.796 0.685 0.924
KPS 10 points 0.100 0.046 4.682 0.030 1.105 1.009 1.210
Comorbidity each point 0.201 0.086 5.442 0.020 0.818 0.690 0.968
Female gender 0.652 0.287 5.180 0.023 1.920 1.095 3.367
and CAPD patients at any six-month time point after sions (Table 4): (i) patients who had undergone un-
planned dialysis initiation; (ii) those dying during the firstdialysis initiation, though the mean urea clearance was
higher in HD patients than CAPD patients at all time year after dialysis initiation; (iii) patients transplanted at
any time after dialysis initiation; (iv) those over the agepoints to 36 months and the difference at 18 months
(2.51  2.46 vs. 2.06  1.98 mL/min, respectively) ap- of 70 at the time of dialysis initiation; (v) diabetics (not
shown in Table 4); and (vi) patients who had any perito-proached statistical significance (P  0.09; Fig. 1). The
same held true for comparisons after the following exclu- nitis episode.
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Fig. 1. Comparison of decline of urea clear-
ance (mean and 95% CI) after dialysis initia-
tion in hemodialysis and continuous ambula-
tory peritoneal dialysis (CAPD) patients in
the first planned modality group. There are
no significant differences (by the Student t
test) between mean urea clearance values in
hemodialysis and CAPD groups at any corre-
sponding time-point.
Table 4. Comparison of mean urea clearances at various time points in hemodialysis (HD) and continuous ambulatory peritoneal dialysis
(CAPD) patients in subgroups of the first planned modality group
Unplanned Early death Transplants 70 years Any peritonitis
HD CAPD HD CAPD HD CAPD HD CAPD HD CAPD
Months on dialysis
0 5.01 (147)a 4.45 (101)a 4.47 (199) 4.34 (119) 4.07 (208) 4.03 (94) 4.63 (165) 4.48 (93) 4.23 (244) 4.08 (52)
6 3.87 (130)a 3.22 (99)a 3.44 (202) 3.09 (118) 3.21 (168) 2.97 (94) 3.42 (147) 3.25 (91) 3.40 (207) 2.86 (47)
12 2.90 (126) 2.56 (105) 2.62 (199) 2.55 (130) 2.53 (161) 2.57 (95) 2.69 (137) 2.59 (97) 2.66 (192) 2.36 (47)
18 2.65 (103) 2.09 (93) 2.51 (162) 2.06 (115) 2.48 (134) 2.20 (81) 2.48 (112) 1.96 (90) 2.57 (157) 1.89 (39)
24 2.51 (85) 2.01 (73) 2.24 (131) 1.91 (92) 2.11 (107) 1.86 (66) 2.29 (89) 1.95 (76) 2.29 (126) 2.15 (27)
30 2.11 (71) 1.77 (62) 1.85 (109) 1.61 (75) 1.81 (90) 1.64 (52) 1.93 (74) 1.59 (63) 1.89 (105) 1.54 (21)
36 1.54 (55) 1.32 (46) 1.48 (84) 1.26 (55) 1.38 (67) 1.47 (39) 1.58 (57) 1.07 (46) 1.49 (83) 1.50 (12)
The subgroups are defined by those patients excluded from the first planned modality group. Numbers in parentheses indicate the number of patients remaining
in each group at each time point.
a Mean urea clearance numbers indicate a significant difference between hemodialysis and CAPD patients
Sole dialysis modality group. The rate of loss of KRU 1 mL/min) at one, two, and three years after dialysis
initiation. Age was a significant determinant of retainedwas identical in HD and CAPD patients. There were no
significant differences in the mean KRU values in HD KRU at one and two years (each decade increase in age,
increased likelihood of retained KRU by 14% and 11%,and CAPD patients at any six-month time point after
dialysis initiation (Fig. 2). The same held true for com- respectively; P  0.001 in both cases). The only other
factor which approached significance was the presenceparisons after the exclusions described above (Table 5).
of chronic interstitial disease, which increased the likeli-
Determinants of loss of KRU hood of retained KRU at one year (but not at 2 and 3
years) by 2.7 times (P 0.078). The mean age of patientsAge, sex, comorbidity severity score, presence or ab-
sence of atheromatous vascular disease, underlying intrin- with chronic interstitial disease was not significantly dif-
ferent from the mean age of patients without this condi-sic renal disease [diabetic nephropathy, chronic glomeru-
lonephritis, chronic interstitial nephritis (which because tion. Dialysis modality had no effect on retention of
KRU in this model.of small numbers included patients with adult polycystic
kidney disease), renovascular disease], mode of dialysis
Other possible factors affecting residual renal functioninitiation (planned or unplanned), and first planned dial-
ysis modality, were modeled by logistic regression to The possibility that potentially nephrotoxic factors
may have adversely affected the rate of loss of KRUdefine the determinants of retained urea clearance (KRU
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Fig. 2. Comparison of decline of urea clear-
ance (mean and 95% CI) after dialysis initia-
tion in hemodialysis and CAPD patients in
the sole dialysis modality group. There are no
significant differences (by the Student t test)
between mean urea clearance values in hemo-
dialysis and CAPD groups at any correspond-
ing time-point
Table 5. Comparison of mean urea clearances at various time points in hemodialysis (HD) and continuous ambulatory peritoneal dialysis
(CAPD) patients in subgroups of the sole dialysis modality group
Unplanned Early death Transplants 70 years Any peritonitis
HD CAPD HD CAPD HD CAPD HD CAPD HD CAPD
Months since initiation
0 5.05 (143) 4.61 (56) 4.48 (191) 4.58 (58) 4.09 (195) 4.44 (35) 4.64 (160) 4.69 (49) 4.23 (240) 4.43 (25)
6 3.91 (127)a 3.07 (55)a 3.50 (195) 3.13 (58) 3.33 (156) 2.95 (38) 3.47 (142) 3.24 (47) 3.43 (203) 2.83 (23)
12 2.94 (121) 2.72 (56) 2.66 (190) 2.65 (62) 2.66 (37) 2.48 (37) 2.73 (132) 2.67 (50) 2.67 (188) 2.49 (26)
18 2.71 (100) 2.29 (50) 2.57 (156) 2.21 (55) 2.58 (124) 2.34 (31) 2.52 (109) 2.29 (45) 2.59 (155) 2.00 (22)
24 2.54 (83) 2.35 (38) 2.30 (126) 2.34 (40) 2.23 (100) 2.42 (21) 2.35 (86) 2.54 (34) 2.32 (124) 2.60 (15)
30 2.14 (70) 1.96 (33) 1.91 (105) 1.96 (33) 1.92 (84) 2.07 (16) 1.98 (72) 2.06 (28) 1.90 (104) 2.11 (12)
36 1.57 (54) 1.07 (26) 1.51 (82) 1.07 (26) 1.43 (64) 1.35 (14) 1.58 (57) 1.03 (21) 1.51 (82) 1.38 (8)
The subgroups are defined by those patients excluded from the sole dialysis modality group. Numbers in parenthesis indicate the number of patients remaining
in each group at each time point.
a Mean urea clearance numbers indicate a significant difference between hemodialysis and CAPD patients
selectively in one of the two modality groups was investi- drugs. There was no difference between two groups with
respect to their exposure to radiographic contrast agentgated. The mean peritonitis rate was 1 in 20 (range 1 in
17 to 1 in 24) patient months. Our peritonitis treatment as indicated by the incidence of coronary, renal or pe-
ripheral arteriograms (15 vs. 14.3%). There was no dif-protocol (IP vancomycin and/or ciprofloxacin) avoids
aminoglycosides. No peritonitis was experienced in 38.6% ference between the groups in the quality of control of
hypertension as indicated by similar average mean bloodof all CAPD patients during the follow-up period. The
rate of fall of KRU was no different in these patients pressure values throughout the study (Table 1).
compared to HD patients (Tables 4 and 5). The use of
Effect of dialysis initiation on the rate of loss ofpotentially nephrotoxic drugs within first two years of
residual renal functiondialysis was no different in the HD and CAPD patients
with respect to ACE-I (55 vs. 59.4%), A2A (2.7 vs. 2.3%), In Figure 3 shows the mean KRU during each six-
aminoglycosides (5.7 vs. 6.3%), or diuretics (64.3 vs. 68%). month period plotted against time in relationship to dial-
Use of NSAIDs was slightly more prevalent in HD group ysis initiation for all patients in the pre-dialysis follow-
(22.3 vs. 16%) but it did not reach statistical significance up group. Although post-dialysis initiation mean KRU
(P  0.12). The drug load (percent of total time on values were consistently slightly higher in the HD than in
dialysis when patients were receiving a drug) also was the CAPD group, the differences between the modalities
was not significantly different at any time point. Fromnot different between modalities for any of the above
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Fig. 3. Comparison of serial mean urea clear-
ance values before and after dialysis initiation
in hemodialysis ( ) and CAPD ( ) patients
in the pre-dialysis follow-up group. Numbers
above the bars are the number of patients with
values in each time period.
Figure 3, it appeared that there was an abrupt decline more rapidly in patients on conventional HD than in
CAPD patients [2–5]. The 28% decline of residual renalin KRU at the time of dialysis initiation. To investigate
this possibility further, we fitted curves through mean function in our CAPD patients during the first post-
initiation year was similar to the 30% decline observedKRU values before and after initiation in a subset of
these data. In order to exclude patients with rapidly by Lysaght et al [3]. The inference thus can be drawn
that residual renal function declines less rapidly duringdeclining renal function cases were selected from the
pre-dialysis follow-up group who had at least one KRU dialysis with high-flux biocompatible membranes than
during dialysis using conventional membranes, althoughvalue at least 18 months prior to dialysis initiation
(Fig. 4). Since there were no differences in the rate of we do not have a control group of conventional HD
patients. This finding is in agreement with those of Mc-decline of KRU in HD and CAPD patients, as outlined
Carthy et al [10] and Hartman et al [11] and in conflictabove, these groups were not distinguished in this subset.
with those of Caramelo et al [8]. In the latter two studiesSeparate exponential curves fitted through pre- and post-
in particular, the number of patients involved was smallinitiation values confirmed the presence of a discontinu-
and duration of observation brief. There also may beity at initiation (Fig. 4). The difference in y-intercept of
some conflict with the findings of Hakim et al [9], al-these curves suggests that dialysis initiation was associ-
though in this latter study, low-flux and not high-flux bio-ated with a step-decline in mean KRU of 1.95 (6.83 to
compatible membranes were compared with bio-incom-4.88) mL/min. Log transformation of the data suggested
patible membranes, and the slope of loss of KRU wasthat, despite the discontinuity at initiation, the rate of
still steeper with the bio-incompatible membrane. All offall KRU was similar pre- and post-initiation (Fig. 4B).
these studies compared the rate of decline of residualThe half-life of KRU pre-initiation was 30 months and
renal function in patients on different hemodialysis re-post-initiation was 27 months.
gimes. No previous study has compared the rate of de-
cline in patients dialyzed using high-flux biocompatible
DISCUSSION membranes and patients on CAPD.
This study demonstrates that residual renal function There is considerable inter-patient variability in the
declines at an identical rate in hemodialysis patients rate of decline of residual renal function in both modal-
treated with high-flux biocompatible membranes and in ities (Figs. 1 and 2). This implies that, if residual renal
CAPD patients. Furthermore, we found that dialysis function is to be taken into account of when an incremen-
modality was not a predictor of retained residual renal tal approach to dialysis initiation is employed in either
function during the first three years of dialysis. Previous modality, it needs to be measured regularly. Assuming
the mean rate of decline risks under-dialysis.studies have shown that residual renal function declines
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nation for this finding is not obvious, though it is possible
that renal disease is more indolent in the elderly. We
did not find that chronic interstitial renal disease, which
also had a protective effect on residual renal function in
this study, was more common in the elderly. A small
proportion of patients in our CAPD group were ulti-
mately transferred to APD in an attempt to maintain
adequacy once residual renal function had diminished.
There are suggestions that the rate of loss of residual
renal function is more rapid in APD than in CAPD
[19, 20]. We do not think this possibility influenced our
findings, since allocation to APD in the small proportion
of patients who received this mode usually occurred after
residual renal function had been substantially lost.
Unlike other studies comparing the rate of decline of
residual renal function in HD and CAPD patients, we
have tried to correct for possible informative censoring.
Informatively censored data occur when the probability
of patient dropout is related to the rate of decline of
residual renal function and hence to underlying GFR.
Misra et al, in an analysis of the CANUSA cohort, found
that CAPD patients who died or were transferred to HD
during follow-up had a more rapid rate of decline of
GFR during follow-up and lower extrapolated GFR at
initiation than patients who completed the study [21].
This would tend to cause an underestimation of the rate
of decline of GFR in the entire group. If this analysis
Fig. 4. Influence of dialysis initiation on the rate of fall of KRU. Sepa- were applied to our data, it would tend understate the
rate exponential curves fitted through pre- () and post- () initiation
rate of decline in the CAPD relative to the HD groupmean residual renal function (KRU) levels (A) suggest a stepped decline
at dialysis initiation. (B) The same data are plotted on a semi-log scale unless similar informative censoring also was occurring
and again suggests a discontinuity at initiation. The rate of decline of in the latter group. We tried to correct for such possible
urea clearance before and after the apparent discontinuity at initiation
effects by comparing the decline of mean urea clearanceappears identical.
in HD and CAPD after the successive exclusion of
groups of patients with such conditions from the main
study groups (Tables 4 and 5). The finding that urea
Preserving residual renal function after dialysis initia- clearance declined at a similar rate in HD and CAPD
tion is a desirable goal. It has many potential benefits in patients held firm under all of our conditions tested.
addition to its utilization in incremental dialysis. Resid- There are a number of reasons why dialysis using high-
ual renal function makes an important contribution to flux biocompatible membranes may contribute to the
the control of interdialytic weight gain, sodium, potas- preservation of residual renal function. Most relate to the
sium, phosphate balance [14], hemoglobin [15], and beta biocompatibility of the hemodialysis process. During con-
2-microglobulin levels [15, 16]. It also plays a crucial role ventional hemodialysis, blood contact with foreign sur-
in maintaining nutritional status [15, 17, 18]. All of these faces provokes a complex sequence of events [22, 23].
factors impinge on morbidity and mortality in the dialysis This involves activation of peripheral blood mononuclear
population. cells, triggering of the complement cascade and the re-
There are some potential problems with the interpre- lease of a whole range of inflammatory mediators includ-
tation of this study. Patients were not randomly allocated ing the proinflammatory cytokines interleukin (IL)-1,
to modality group, as the choice of modality was deter- IL-6 and tumor necrosis factor-	 (TNF	), reactive oxy-
mined by patient choice subject to clinical imperatives gen species (ROS) and nitric oxide (NO). The resulting
as described earlier in this article. Thus, the HD and acute inflammatory response is marked by the release
CAPD groups were not matched for age, comorbidity, of acute phase reactants including serum amyloid A and
dependency, and mode of initiation (planned or un- C-reactive protein (CRP). Hence bio-incompatibility
planned). Of these, only age appeared to have an effect may be an important contributor to the elevated CRP
on the rate of loss of residual renal function, as increased levels that correlate with malnutrition [24, 25], cardiovas-
cular risk [26], and increased mortality [27]. Many ofage seems to protect against loss of function. The expla-
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these proinflammatory effects are abrogated by the use renal function declines after dialysis initiation at a rate
indistinguishable from that in CAPD. This contrasts withof synthetic membranes [28, 29] and perhaps by reuse.
Use of synthetic membranes may reduce mortality in previous studies, which have shown more rapid decline
of residual renal function in conventional hemodialysismaintenance hemodialysis [30, 31]. Dialysis fluid quality
also is important. Exposure to endotoxin and other small than in CAPD. We cannot be certain of individual contri-
butions of each component of this dialysis, namely bicar-molecular weight (5 kD) cytokine-inducing substances
(CIS) has been implicated in these proinflammatory bonate buffer, biocompatible membrane, high flux dial-
ysis or ultrapure water. Residual renal function appearsevents. Use of ultrapure water may reduce the inflam-
matory stimulus [32]. Paradoxically, polysulphone and to decline at a similar rate in the pre- and post-dialysis
initiation phases, though a step-decline at initiation mayother synthetic high-flux membranes are less permeable
than low-flux cuprophane to CIS because of a higher occur at least in some patients. These data may have
important implications for the practice of incrementaldegree of membrane adsorption of the hydrophobic CIS,
due in part to the increased thickness and denser protein dialysis and on current ideas about the optimum choice
of initial dialysis modality [36].coating of the synthetic membranes [33]. It perhaps
would be surprising if this inflammatory milieu, with the
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profound clinical effects described, did not contribute to tal, Stevenage, Herts, England SG1 4AB, United Kingdom.
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